DYNE THERAPEUTICS INC

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

23 Mar 2023 07:30:17 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference

20 Mar 2023 07:30:24 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Upcoming Investor Conferences

07 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

02 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

03 Nov 2022 07:30:01 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Investor Conferences in November

02 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

31 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress

11 Oct 2022 16:10:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

27 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual Event

12 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

06 Sep 2022 16:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

06 Sep 2022 07:01:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

06 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development

29 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

10 Aug 2022 07:30:41 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

04 Aug 2022 07:30:01 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

12 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

05 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

03 Jun 2022 07:30:00 By Nasdaq GlobeNewswire